Literature DB >> 31248862

Improving Detection of Multiple Sclerosis Lesions in the Posterior Fossa Using an Optimized 3D-FLAIR Sequence at 3T.

A Lecler1, I El Sanharawi2, J El Methni3, O Gout4, P Koskas2, J Savatovsky2.   

Abstract

BACKGROUND AND
PURPOSE: There is no consensus regarding the best MR imaging sequence for detecting MS lesions. The aim of our study was to assess the diagnostic value of optimized 3D-FLAIR in the detection of infratentorial MS lesions compared with an axial T2-weighted imaging, a 3D-FLAIR with factory settings, and a 3D double inversion recovery sequence.
MATERIALS AND METHODS: In this prospective study, 27 patients with confirmed MS were included. Two radiologists blinded to clinical data independently read the following sequences: axial T2WI, 3D double inversion recovery, standard 3D-FLAIR with factory settings, and optimized 3D-FLAIR. The main judgment criterion was the overall number of high-signal-intensity lesions in the posterior fossa; secondary objectives were the assessment of the reading confidence and the measurement of the contrast. A nonparametric Wilcoxon test was used to compare the MR images.
RESULTS: Twenty-two patients had at least 1 lesion in the posterior fossa. The optimized FLAIR sequence detected significantly more posterior fossa lesions than any other sequence: 7.5 versus 5.8, 4.8, and 4.1 (P values of .04, .03, and .03) with the T2WI, the double inversion recovery, and the standard FLAIR, respectively. The reading confidence index was significantly higher with the optimized FLAIR, and the contrast was significantly higher with the optimized FLAIR than with the standard FLAIR and the double inversion recovery.
CONCLUSIONS: An optimized 3D-FLAIR sequence improved posterior fossa lesion detection in patients with MS.
© 2019 by American Journal of Neuroradiology.

Entities:  

Mesh:

Year:  2019        PMID: 31248862      PMCID: PMC7048546          DOI: 10.3174/ajnr.A6107

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  48 in total

1.  Measuring signal-to-noise ratio in partially parallel imaging MRI.

Authors:  Frank L Goerner; Geoffrey D Clarke
Journal:  Med Phys       Date:  2011-09       Impact factor: 4.071

2.  An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers.

Authors:  J R Landis; G G Koch
Journal:  Biometrics       Date:  1977-06       Impact factor: 2.571

Review 3.  Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process.

Authors:  Àlex Rovira; Mike P Wattjes; Mar Tintoré; Carmen Tur; Tarek A Yousry; Maria P Sormani; Nicola De Stefano; Massimo Filippi; Cristina Auger; Maria A Rocca; Frederik Barkhof; Franz Fazekas; Ludwig Kappos; Chris Polman; David Miller; Xavier Montalban
Journal:  Nat Rev Neurol       Date:  2015-07-07       Impact factor: 42.937

4.  Correlation of multiple sclerosis measures derived from T2-weighted, T1-weighted, magnetization transfer, and diffusion tensor MR imaging.

Authors:  G Iannucci; M Rovaris; L Giacomotti; G Comi; M Filippi
Journal:  AJNR Am J Neuroradiol       Date:  2001-09       Impact factor: 3.825

5.  Magnetic resonance imaging of multiple sclerosis: a study of pulse-technique efficacy.

Authors:  V M Runge; A C Price; H S Kirshner; J H Allen; C L Partain; A E James
Journal:  AJR Am J Roentgenol       Date:  1984-11       Impact factor: 3.959

Review 6.  Magnetic resonance techniques for the in vivo assessment of multiple sclerosis pathology: consensus report of the white matter study group.

Authors:  Massimo Filippi; Andrea Falini; Douglas L Arnold; Franz Fazekas; Oded Gonen; Jack H Simon; Vincent Dousset; Mario Savoiardo; Jerry S Wolinsky
Journal:  J Magn Reson Imaging       Date:  2005-06       Impact factor: 4.813

Review 7.  Measurement and clinical effect of grey matter pathology in multiple sclerosis.

Authors:  Jeroen J G Geurts; Massimiliano Calabrese; Elizabeth Fisher; Richard A Rudick
Journal:  Lancet Neurol       Date:  2012-12       Impact factor: 44.182

8.  Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis.

Authors:  Arjan Minneboo; Frederick Barkhof; Chris H Polman; Bernard M J Uitdehaag; Dirk L Knol; Jonas A Castelijns
Journal:  Arch Neurol       Date:  2004-02

9.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

Review 10.  Gray matters in multiple sclerosis: cognitive impairment and structural MRI.

Authors:  Silvia Messina; Francesco Patti
Journal:  Mult Scler Int       Date:  2014-01-22
View more
  3 in total

1.  Sensitive Detection of Infratentorial and Upper Cervical Cord Lesions in Multiple Sclerosis with Combined 3D FLAIR and T2-Weighted (FLAIR3) Imaging.

Authors:  R E Gabr; J A Lincoln; A Kamali; O Arevalo; X Zhang; X Sun; K M Hasan; P A Narayana
Journal:  AJNR Am J Neuroradiol       Date:  2020-10-08       Impact factor: 3.825

2.  Optimizing 3D FLAIR to detect MS lesions: pushing past factory settings for precise results.

Authors:  Augustin Lecler; C Bouzad; R Deschamps; F Maizeroi; J C Sadik; A Gueguen; O Gout; H Picard; J Savatovsky
Journal:  J Neurol       Date:  2019-08-01       Impact factor: 4.849

3.  Evaluation of Ultrafast Wave-Controlled Aliasing in Parallel Imaging 3D-FLAIR in the Visualization and Volumetric Estimation of Cerebral White Matter Lesions.

Authors:  C Ngamsombat; A L M Gonçalves Filho; M G F Longo; S F Cauley; K Setsompop; J E Kirsch; Q Tian; Q Fan; D Polak; W Liu; W-C Lo; R Gilberto González; P W Schaefer; O Rapalino; J Conklin; S Y Huang
Journal:  AJNR Am J Neuroradiol       Date:  2021-07-08       Impact factor: 4.966

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.